Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesGenetics
You have accessRestricted Access

Complement Mutations in Diacylglycerol Kinase-ε–Associated Atypical Hemolytic Uremic Syndrome

Daniel Sánchez Chinchilla, Sheila Pinto, Bernd Hoppe, Marta Adragna, Laura Lopez, Maria Luisa Justa Roldan, Antonia Peña, Margarita Lopez Trascasa, Pilar Sánchez-Corral and Santiago Rodríguez de Córdoba
CJASN September 2014, 9 (9) 1611-1619; DOI: https://doi.org/10.2215/CJN.01640214
Daniel Sánchez Chinchilla
*Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain;
†Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheila Pinto
*Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain;
†Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Hoppe
‡Department of Pediatrics, Division of Pediatric Nephrology, University of Bonn, Bonn, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Adragna
§Department of Nephrology, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Lopez
§Department of Nephrology, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Luisa Justa Roldan
‖Servicio de Nefrología Pediátrica, Hospital Universitario Infantil Miguel Servet, Zaragoza, Spain; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonia Peña
¶Servicio de Nefrología Pediátrica,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margarita Lopez Trascasa
†Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain;
**Unidad de Inmunología, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pilar Sánchez-Corral
††Unidad de Investigación, Hospital Universitario La Paz/Instituto de Investigación Hospital Universitario La Paz, Madrid, Spain
†Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santiago Rodríguez de Córdoba
*Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain;
†Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Background and objectives Atypical hemolytic uremic syndrome is characterized by vascular endothelial damage caused by complement dysregulation. Consistently, complement inhibition therapies are highly effective in most patients with atypical hemolytic uremic syndrome. Recently, it was shown that a significant percentage of patients with early-onset atypical hemolytic uremic syndrome carry mutations in diacylglycerol kinase-ε, an intracellular protein with no obvious role in complement. These data support an alternative, complement-independent mechanism leading to thrombotic microangiopathy that has implications for treatment of early-onset atypical hemolytic uremic syndrome. To get additional insights into this new form of atypical hemolytic uremic syndrome, the diacylglycerol kinase-ε gene in a cohort with atypical hemolytic uremic syndrome was analyzed.

Design, setting, participants, & measurements Eighty-three patients with early-onset atypical hemolytic uremic syndrome (<2 years) enrolled in the Spanish atypical hemolytic uremic syndrome registry between 1999 and 2013 were screened for mutations in diacylglycerol kinase-ε. These patients were also fully characterized for mutations in the genes encoding factor H, membrane cofactor protein, factor I, C3, factor B, and thrombomodulin CFHRs copy number variations and rearrangements, and antifactor H antibodies.

Results Four patients carried mutations in diacylglycerol kinase-ε, one p.H536Qfs*16 homozygote and three compound heterozygotes (p.W322*/p.P498R, two patients; p.Q248H/p.G484Gfs*10, one patient). Three patients also carried heterozygous mutations in thrombomodulin or C3. Extensive plasma infusions controlled atypical hemolytic uremic syndrome recurrences and prevented renal failure in the two patients with diacylglycerol kinase-ε and thrombomodulin mutations. A positive response to plasma infusions and complement inhibition treatment was also observed in the patient with concurrent diacylglycerol kinase-ε and C3 mutations.

Conclusions Data suggest that complement dysregulation influences the onset and disease severity in carriers of diacylglycerol kinase-ε mutations and that treatments on the basis of plasma infusions and complement inhibition are potentially useful in patients with combined diacylglycerol kinase-ε and complement mutations. A comprehensive understanding of the genetic component predisposing to atypical hemolytic uremic syndrome is, therefore, critical to guide an effective treatment.

  • complement
  • genetic renal disease
  • hemolytic uremic syndrome

Introduction

Hemolytic uremic syndrome (HUS) is a rare, life-threatening disease characterized by thrombocytopenia, hemolytic anemia, and acute renal failure (1). The most frequent form of HUS follows a diarrheal prodrome and is associated with infections involving shiga toxin–producing Escherichia coli strains. Five to ten percent of patients with HUS lack an association with this type of infection. This atypical form of HUS (aHUS) has the poorest long-term prognosis; it is characterized by recurrences and presents a mortality rate approaching 30% (1,2). Genetic analyses in patients with aHUS have revealed that most cases associate with mutations and polymorphisms in complement genes and that the disease develops as a consequence of defective protection of cellular surfaces from complement activation (3–17). The recognition that aHUS is a disorder involving complement-dependent tissue damage provided strong support for the implementation of aHUS therapies based in complement inhibitors (18).

In contrast to this complement-related aHUS, Lemaire et al. (19) have reported that as many as 27% of aHUS cases presenting in the first 1 year of life are caused by the deficiency of diacylglycerol kinase-ε (DGK-ε) encoded by the diacylglycerol kinase-ε (DGKE) gene. It has been proposed that lack of DGK-ε causes enhanced signaling through AA-containing DAGs and results in a prothrombotic phenotype (19,20). Because these patients lacked discernible complement alterations, it was suggested that DGKE-associated aHUS represents an alternative mechanism leading to thrombotic microangiopathy that is independent of complement dysregulation (19).

To get additional insights into this new form of aHUS and estimate the prevalence of carriers of DGKE mutations in the aHUS Spanish cohort, we performed analysis of the DGKE gene in 83 patients with a disease onset in the first 2 years of life.

Materials and Methods

Patients

Our aHUS cohort includes patients, mainly of Spanish origin, enrolled since 1999. We have performed complement studies that have allowed us to identify mutations, risk haplotypes, and autoantibodies in these patients, most of which have already been published. Currently, our cohort includes 289 patients with aHUS: 262 patients from Spain, 9 patients from other European countries, 4 patients from north Africa (Morocco, Tunisia, and Senegal), 6 patients from the United States, and 8 patients from South America. All these patients were diagnosed at specific centers in the countries mentioned and subsequently submitted to the Spanish aHUS registry for complement functional and genetic analyses. aHUS was diagnosed on the basis of microangiopathic hemolytic anemia and thrombocytopenia defined by an hematocrit <0.3 (30%), hemoglobin level <10 g/dl, serum lactate dehydrogenase level >460 units/L, undetectable haptoglobin level, fragmented erythrocytes in the peripheral blood smear, and platelet count <150,000/μl associated with acute renal failure. The studies reported here have the approval of the Institutional Review Board. Informed consent was provided by all individuals participating in the study according to the Declaration of Helsinki.

Complement Profile Assessment

Serum concentrations of C3 and C4 were evaluated by nephelometry (Siemens, Marburg, Germany). Factor H (FH) and factor I (FI) serum levels were measured by ELISA (21,22). Membrane cofactor protein (MCP; CD46) levels on peripheral blood cells were determined by flow cytometry (8). The presence of anti-FH antibodies and C3 nephritic factor and the functional analysis of FH using the sheep erythrocytes hemolysis assay were performed as previously described (23–25).

Mutation Screening and Genotyping

Exons of the genes encoding factor H (CFH), membrane cofactor (MCP), factor I (CFI), C3 (C3), factor B (CFB), and thrombomodulin (THBD) were amplified from genomic DNA using primers derived from the intronic sequences as described (5,10,11,13,26). Exons of DGKE were amplified with the primers described in Supplemental Table 1. Automatic sequencing was performed in an ABI3730 sequencer using a dye terminator cycle sequencing kit (Applied Biosystems). Copy number variations and genomic rearrangements were assessed by multiplex ligation-dependent probe amplification and custom-designed high-density 8×15,000 oligonucleotide CGH arrays spanning the RCA gene cluster (median resolution=110 bp; AMADID 040193; Agilent Technologies, Santa Clara, CA) (27). CFH and MCP genotyping was performed as described previously (8).

In Silico Analyses of Mutations

The probability of a genetic variant resulting in structural or functional alterations was calculated using bioinformatics prediction tools that discriminate neutral polymorphisms from amino acid substitutions of likely functional importance. To minimize the possibility of false-positive or false-negative results, we have applied four different computational algorithms publicly available: Sorting Intolerant from Tolerant (28) (SIFT; http://sift.jcvi.org), Polymorphism Phenotyping (29) (PolyPhen; http://genetics.bwh.harvard.edu), Mutation Taster (30) (http://www.mutationtaster.org), and Align-GVGD (31) (http://agvgd.iarc.fr). The SIFT algorithm predicts whether an amino acid substitution affects protein function on the basis of sequence homology among related genes and domains over evolutionary time and the physicochemical properties of the amino acid residues. PolyPhen also incorporates the analyses of sequence conservation and the nature of the amino acid residues involved as well as the location of the substitution within the structure of the protein. By accessing a variety of heterogeneous biologic databases and analytical tools, Mutation Taster is able to identify the missense mutations most likely to have functional effects, such as changes to the transcriptional level and pre-mRNA splicing. Align-GVGD combines the biophysical characteristics of amino acid and protein multiple sequence alignments to predict where missense substitutions in genes of interest fall in a spectrum from enriched deleterious to enriched neutral.

Results

The Spanish aHUS cohort includes 83 patients enrolled between 1999 and 2013 with a disease onset in the first 2 years of life; 62 of these patients do not have a discernible genetic or autoimmune abnormality that helps to explain the development of the disease. We performed the analysis of the DGKE gene and found that one of these patients (HUS299) was a homozygote for a frameshift DGKE mutation. We also screened 21 patients with early-onset aHUS with identified genetic factors and surprisingly, found 3 additional patients belonging to two unrelated pedigrees carrying compound heterozygous mutations in DGKE (Figures 1 and 2, Table 1). We did not find heterozygote carriers of DGKE mutations in our aHUS cohort.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Pedigrees of patients with atypical hemolytic uremic syndrome carrying diacylglycerol kinase-ε (DGKE) mutations. For each pedigree, the index patients are indicated with arrows, and the chromatograms for the corresponding mutations are shown. Segregation of the mutations is indicated with colored symbols. HUS, hemolytic uremic syndrome; ND, genetic analyses have not yet been performed.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Location of the diacylglycerol kinase-ε mutations found in Spanish patients with atypical hemolytic uremic syndrome (aHUS). A diagram of the diacylglycerol kinase-ε protein depicting the different protein domains is shown. Arrows identify the positions of the five mutations found in the screening of the early-onset Spanish patients with aHUS. C1 domain, kinase catalytic domain and kinase accessory domain; HD, hydrophobic domain.

View this table:
  • View inline
  • View popup
Table 1.

Diacylglycerol kinase-ε and complement gene mutations found in patients with early-onset atypical hemolytic uremic syndrome

Patients with Isolated DGKE Mutations

HUS299 is a 4-year-old boy from Morocco who presented with aHUS at 13 months, coincident with a diarrhea episode. He required peritoneal dialysis for 22 days but evolved well without recurrences. Three years after remission, the patient remains asymptomatic, with only a residual microalbuminuria (Table 2, Supplemental Material). HUS299 is homozygous for a frameshift mutation in exon 12 (c.1608_1609del; p.H536Qfs*16) of DGKE that results in a truncated DGK-ε protein lacking the last 31 amino acids (Figures 1 and 2, Table 1), which is very likely deleterious. This novel DGKE genetic variation was not found in 80 control chromosomes from North African populations, and it is not described in the available databases. Additional genetic analysis in this patient failed to reveal other genetic abnormalities. He was also negative for anti-FH autoantibodies, and his plasma complement protein levels, including C3, were normal (Table 3).

View this table:
  • View inline
  • View popup
Table 2.

Clinical characteristics of the patients with atypical hemolytic uremic syndrome carrying diacylglycerol kinase-ε mutations

View this table:
  • View inline
  • View popup
Table 3.

Complement profiles in patients with atypical hemolytic uremic syndrome carrying mutations in diacylglycerol kinase-ε

Patients with Concurrent Mutations in DGKE and THBD

HUS40 and HUS39 are siblings from an Argentinean family of European ancestry. HUS40 presented with HUS at 7 months of age. Five months later, she had a recurrence that required hemodialysis and continuous ambulatory peritoneal dialysis for a few months. She evolved satisfactorily, partially recovering renal function without dialysis requirement. A third recurrence occurred at 2 years of age that responded well to a protocol of daily plasma infusions, which were suspended 1 year later. She did not suffer any more recurrences. She is now 17 years old and clinically well, with normal blood parameters, serum creatinine of 1.5 mg/dl, and Ccr of 41 ml/min per 1.73 m2 (Table 2, Supplemental Material). Her brother, HUS39, presented with aHUS at 3 months. He was anuric, requiring acute peritoneal dialysis. On the basis of the experience with his sister (HUS40), he was immediately treated with daily plasma infusions. After 10 days, his renal function improved, and he was discharged, maintaining the daily plasma infusions for 2 months (10 ml/kg per day). Interestingly, when plasma infusions were spaced biweekly, he had an aHUS recurrence that responded well when plasma infusions were returned to daily basis. On the basis of his clinical improvement, plasma infusions were again spaced progressively and finally suspended 5 years later. He is now 11 years old and clinically well, with normal blood parameters, serum creatinine of 0.8 mg/dl, and Ccr of 57 ml/min per 1.73 m2 (Table 2, Supplemental Material).

HUS40 and HUS39 are compound heterozygotes for a nonsense mutation (c.966G>A; p.W322*) in exon 6 and a missense mutation (c.1493C>G; p.P498R) in exon 11 of the DGKE gene (Figures 1 and 2, Table 1). The p.W322* mutation has been described previously as a pathogenic mutation associated with a rare European haplotype (19). Interestingly, the p.W322* mutation in our patients is also associated with the same DGKE haplotype (Supplemental Table 2). The second mutation p.P498R is a novel genetic variation that results in an amino acid substitution in exon 11 of the DGKE gene, a region that encodes the kinase accessory domain (Figure 2). p.P498R was not found in 140 normal control chromosomes and has not been reported previously in the available DGKE mutation databases. We lack assays to test the functionality of the DGKE mutations and have no biopsy material from the patients to test DGK-ε expression. However, a very strong argument supporting that p.P498R is a DGKE deleterious mutation is that the patients carrying this mutation presented it together with the deleterious p.W322* mutation (patients are compound heterozygotes), which is in agreement with the recessive model of inheritance described for pathogenic DGKE mutations. It would be extremely unlikely that this pairing of mutations would have occurred by chance if such infrequent genetic variants were not pathogenic. Furthermore, we have used bioinformatics prediction tools that discriminate neutral polymorphisms from amino acid substitutions of likely functional importance to support that the identified DGKE changes represent true disease mutations (Materials and Methods). These in silico analyses indicate that p.P498R is a damaging mutation (Table 4).

View this table:
  • View inline
  • View popup
Table 4.

In silico analyses of missense mutations

Genetic analyses in these patients revealed that both patients are also heterozygotes for a mutation in THBD (c.1456G>T; p.D486Y) previously found associated with aHUS and shown to be pathogenic (16) (Figure 1). CFH and MCP genotyping showed that HUS39 and HUS40 are heterozygotes for the MCP and CFH aHUS risk haplotypes, respectively. The search for anti-FH autoantibodies was negative, and the complement plasma levels were normal, although C3 levels in these individuals, particularly HUS40, were in the lower part of the normal range (Table 3).

Patients with Concurrent Mutations in DGKE and C3

HUS272 is a 4-year-old girl from a German–Spanish family who presented with aHUS at 8 months of age, coincident with an upper respiratory tract infection. She had periorbital edema, low plasma total protein levels, hematuria, and nephrotic proteinuria (Table 2). After 48 hours, she developed generalized edema, hypertension, and thrombocytopenia, and schistocytes were observed at the peripheral blood smear. A biopsy supported the diagnosis of aHUS. She evolved favorably with a progressive decrease of proteinuria levels. Eight months later, coincident with a vaccination, she suffered an episode of oliguria and edema associated with increased proteinuria, which resolved by raising the Enalapril doses. However, 3 months later, after an acute upper tract infection, she had an aHUS recurrence, and her clinical situation deteriorated. C3 was slightly below the normal range. She initiated biweekly plasma infusions, which led to stabilization of the clinical symptoms and near normalization of all blood parameters (Figure 3); however, proteinuria and gross hematuria persisted. One year later, C3 levels dropped to 0.77 g/L, the edema returned, and her clinical situation worsened again. It was decided to switch her from the biweekly plasma infusions to Eculizumab treatment, and thereafter, her clinical situation improved significantly. However, a urine sample revealed ongoing proteinuria. She is currently treated biweekly with Eculizumab, and the clinical situation had improved. Previously, she always had peripheral edema when she had infections; under Eculizumab treatment, however, she remained without obvious edema (Table 2, Supplemental Material).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Evolution of blood parameters in hemolytic uremic syndrome 272 (HUS272). The evolution of the (A) C3, (B) platelets, and (C) lactate dehydrogenase (LDH) serum levels in patient HUS272 from the disease onset are shown. Arrows indicate the start of the plasma therapy (fresh frozen plasma [FFP]) and the Eculizumab (Ecu) treatment. C3 levels in the mother (Mo) and father (Fa) are also indicated.

Genetic analysis showed that HUS272 is a compound heterozygote for a nonsense mutation (c.1452del; p.G484Gfs*10) in exon 11 of DGKE that truncates the last 69 amino acids of the protein (most likely deleterious) and a missense mutation (c.744G>C; p.Q248H) in exon 4 of the DGKE gene, encoding the kinase catalytic domain of DGK-ε (Figures 1 and 2, Table 1). p.G484Gfs*10 and p.Q248H are novel mutations that were not found in 140 normal control chromosomes and have not been reported previously in the available DGKE mutation databases. Similar to the case of the p.P498R mutation found in HUS40 and HUS39, the concurrence of p.G484Gfs*10 and p.Q248H in HUS272 and the results of their analysis in silico strongly support that these DGKE mutations are pathogenic (Table 4).

Critically, the analyses of all known aHUS genetic risk factors showed that HUS272 carries, in addition to the DGKE mutations, a novel mutation in the C3 gene (c.784G>T; p.G262W) (Figure 1) that, in silico analysis, is also clearly identified as a damaging mutation (Table 4). p.G262W was not found in 140 normal control chromosomes and is not included in genetic variation databases. Interestingly, this patient carries the C3 mutation combined with an MCP risk haplotype in homozygosity (Table 3), which is characteristic of patients with aHUS carrying gain-of-function mutations in C3 and CFB (13,32). Complement plasma levels were normal, although C3 levels in this patient were always below or in the lower part of the normal range (Table 3). Notably, her mother, who is also a carrier of the p.G262W C3 mutation, also presents decreased plasma C3 levels (Figure 3A).

Discussion

Previous studies have identified two groups of patients with mutations in the DGKE gene. Ozaltin et al. (20) reported nine patients from three consanguineous pedigrees presenting with membranoproliferative GN with histologic signs of both glomerular microangiopathy and endothelial distress at ages ranging from 0.8 to 17 years old. No complement data were reported for these patients (20). A second study by Lemaire et al. (19) reported 13 patients from nine unrelated pedigrees also carrying mutations in DGKE. In contrast, all these patients presented within the first 1 year of life with aHUS. Notably, these patients belong to a group of pediatric-onset aHUS that was selected to include only patients in whom mutation in known aHUS-associated genes or anti-FH autoantibodies has not been identified (19). Here, we have analyzed the DGKE gene in our aHUS cohort and found that 5% (4 of 83) of our early-onset patients carry DGKE mutations, including both carriers and noncarriers of mutations in other aHUS-associated genes.

Disease presentation and evolution in our four patients was comparable with that of the patients carrying DGKE mutations described by Lemaire et al. (19) These patients met the clinical criteria for aHUS at presentation and had disease recurrences within early childhood. Later, one patient clearly progressed to chronic glomerulopathy with hematuria, proteinuria, hypertension, and renal failure, which is distinctive of DGKE mutation carriers from other patients with aHUS (Table 2).

Interestingly, we found that three of our patients also carry mutations in other known aHUS-associated genes. Clinical course and severity of the disease in these patients were different from those in the patient with isolated DGKE mutations. HUS39 and HUS40, who also carry a pathogenic heterozygous mutation in THBD, had various aHUS recurrences shortly after the disease onset that responded well to daily plasma infusions. Notably, the course of the disease was more benign in the affected brother (HUS39), who was intensively treated with plasma immediately after the onset of the disease (Table 2). These data point to a potential beneficial effect of plasma infusions in our patients and argue against previous remarks (on the basis of data from patients carrying exclusively loss-of-function DGKE mutations) not supporting the use of plasma in affected carriers of DGKE mutations (19). Notably, it has been reported that most (88%) patients with aHUS associated with THBD mutations responded well to plasma therapy (33). Therefore, we suggest that the association of a THBD mutation with the DGKE mutations in HUS39 and HUS40 results in a potentially more severe phenotype because of an increased frequency of aHUS recurrences caused by the THBD mutation. Consistent with other patients with aHUS carrying THBD mutations, our patients responded well to plasma therapy.

HUS272, who in addition to the DGKE mutations, also carries a likely pathogenic heterozygous mutation in C3 and the MCP risk haplotype in homozygosity, presented several aHUS recurrences shortly after onset. Biweekly plasma infusions were effective in normalizing blood parameters, and subsequent Eculizumab treatment resolved the infection-associated edemas that were typical in this patient (Figure 3). Compared with the other patients with DGKE mutations in this case series, the association of a C3 gene mutation in this particular patient possibly contributed to more severe disease with chronic activation of thrombotic microangiopathy despite plasma treatment and more importantly, a positive response to complement C5 blockage with Eculizumab, which was conducted to remission.

Finally, HUS299, carrying exclusively DGKE mutations, recovered renal function without plasma infusions or Eculizumab treatment and has remained stable without recurrences since the aHUS onset 3 years ago (Table 2).

These findings support a potential role of mutations in complement genes in patients carrying DGKE loss-of-function mutations. The novelty of our approach is searching for DGKE mutations in patients with aHUS with and without mutations in known aHUS-associated complement genes. It is remarkable that, after screening 83 patients with aHUS with a very early onset (<2 years) without excluding those patients with previously identified mutations in known aHUS-associated genes (21 patients), we found 3 patients carrying recessive DGKE mutations who also carry mutations in other known aHUS-associated genes and just 1 patient with isolated DGKE mutations. These data and the evident correlation of disease recurrences with infection in our patients (Supplemental Material) suggest that the onset and severity of the chronic renal pathology associated with DGKE mutations may be influenced by additional complement-related aHUS risk factors. If these data are replicated in other aHUS cohorts and a role for complement dysregulation is finally established in DGKE-related aHUS, the suggestion that current treatment on the basis of plasma therapy and complement inhibition are not beneficial in individuals with DGKE mutations should, perhaps, be reconsidered, at least for patients with coexistence of DGKE and complement gene mutations. Preventing complement-related thrombotic microangiopathy episodes may result in a more benign course of the renal disease in carriers of DGKE mutations.

In conclusion, we found that 5% of the patients in our aHUS cohort who had a very early onset of the disease (<2 years) carry recessive mutations in DGKE. Although this percentage is small compared with 27%, which was reported for the French cohort, it is still a significant number. Our patients carry a total of five different mutations in the DGKE gene. Four of them are novel mutations, and one (p.W322*) mutation seems to be a relatively prevalent mutation of European origin. The disease presentation and evolution in our patients was comparable with that of patients carrying DGKE mutations described by Lemaire et al. (19) in the French aHUS cohort. However, in contrast with that previous study, we found that three of our patients carry additional mutations in the known aHUS candidate genes C3 and THBD. Although additional analyses in other aHUS cohorts are needed to replicate our findings, these data suggest that complement-mediated aHUS episodes have a role in modulating the onset and severity of renal disease in carriers of DGKE mutations. Finally, this work also illustrates that a comprehensive understanding of the genetic component predisposing to the pathology is critical to guide appropriate diagnostics and effective treatment in aHUS.

Disclosures

B.H., M.A., L.L., and S.R.d.C. have received honoraria from Alexion Pharmaceuticals for giving lectures and participating in advisory boards. None of these activities has had any influence on the results or interpretation in this article. The remaining authors declare no conflicts of interest.

Acknowledgments

We thank the patients and their relatives for their participation in this study. We also thank Dr. Gema Ariceta for comments and suggestions during the preparation of this manuscript. We thank Drs. J. Perez and L. Olavarrieta from Secugen SL for invaluable help in the design for the diacylglycerol kinase-ε sequencing strategy.

Work in this report was funded by Spanish “Ministerio de Economía y Competitividad” Grants SAF2011-26583, PS09/00122 (to M.L.T.), SAF2012-38636 (to M.L.T.), and PI1200597 (to P.S.-C.) and Fundación Renal Iñigo Alvarez de Toledo and Seventh Framework Programme European Union Project EURenOmics Grant 305608 (to S.R.d.C.). In addition, this work was supported by Autonomous Region of Madrid Grant S2010/BMD-2316 (to M.L.T., P.S.-C., and S.R.d.C.).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.01640214/-/DCSupplemental.

  • See related editorial, “Factors Influencing Treatment of Atypical Hemolytic Uremic Syndrome,” on pages 1516–1518.

  • Received February 12, 2014.
  • Accepted May 12, 2014.
  • Copyright © 2014 by the American Society of Nephrology

References

  1. ↵
    1. Noris M,
    2. Remuzzi G
    : Hemolytic uremic syndrome. J Am Soc Nephrol 16: 1035–1050, 2005pmid:15728781
    OpenUrlFREE Full Text
  2. ↵
    1. Constantinescu AR,
    2. Bitzan M,
    3. Weiss LS,
    4. Christen E,
    5. Kaplan BS,
    6. Cnaan A,
    7. Trachtman H
    : Non-enteropathic hemolytic uremic syndrome: Causes and short-term course. Am J Kidney Dis 43: 976–982, 2004pmid:15168377
    OpenUrlCrossRefPubMed
  3. ↵
    1. Caprioli J,
    2. Bettinaglio P,
    3. Zipfel PF,
    4. Amadei B,
    5. Daina E,
    6. Gamba S,
    7. Skerka C,
    8. Marziliano N,
    9. Remuzzi G,
    10. Noris M,
    11. Itaslian Registry of Familial and Recurrent HUS/TTP
    : The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 12: 297–307, 2001pmid:11158219
    OpenUrlAbstract/FREE Full Text
    1. Caprioli J,
    2. Castelletti F,
    3. Bucchioni S,
    4. Bettinaglio P,
    5. Bresin E,
    6. Pianetti G,
    7. Gamba S,
    8. Brioschi S,
    9. Daina E,
    10. Remuzzi G,
    11. Noris M,
    12. International Registry of Recurrent and Familial HUS/TTP
    : Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12: 3385–3395, 2003pmid:14583443
    OpenUrlCrossRefPubMed
  4. ↵
    1. Pérez-Caballero D,
    2. González-Rubio C,
    3. Gallardo ME,
    4. Vera M,
    5. López-Trascasa M,
    6. Rodríguez de Córdoba S,
    7. Sánchez-Corral P
    : Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 68: 478–484, 2001pmid:11170895
    OpenUrlCrossRefPubMed
    1. Richards A,
    2. Buddles MR,
    3. Donne RL,
    4. Kaplan BS,
    5. Kirk E,
    6. Venning MC,
    7. Tielemans CL,
    8. Goodship JA,
    9. Goodship TH
    : Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 68: 485–490, 2001pmid:11170896
    OpenUrlCrossRefPubMed
    1. Warwicker P,
    2. Goodship TH,
    3. Donne RL,
    4. Pirson Y,
    5. Nicholls A,
    6. Ward RM,
    7. Turnpenny P,
    8. Goodship JA
    : Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53: 836–844, 1998pmid:9551389
    OpenUrlCrossRefPubMed
  5. ↵
    1. Esparza-Gordillo J,
    2. Goicoechea de Jorge E,
    3. Buil A,
    4. Carreras Berges L,
    5. López-Trascasa M,
    6. Sánchez-Corral P,
    7. Rodríguez de Córdoba S
    : Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 14: 703–712, 2005pmid:15661753
    OpenUrlCrossRefPubMed
    1. Noris M,
    2. Brioschi S,
    3. Caprioli J,
    4. Todeschini M,
    5. Bresin E,
    6. Porrati F,
    7. Gamba S,
    8. Remuzzi G,
    9. International Registry of Recurrent and Familial HUS/TTP
    : Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362: 1542–1547, 2003pmid:14615110
    OpenUrlCrossRefPubMed
  6. ↵
    1. Richards A,
    2. Kemp EJ,
    3. Liszewski MK,
    4. Goodship JA,
    5. Lampe AK,
    6. Decorte R,
    7. Müslümanoğlu MH,
    8. Kavukcu S,
    9. Filler G,
    10. Pirson Y,
    11. Wen LS,
    12. Atkinson JP,
    13. Goodship TH
    : Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100: 12966–12971, 2003pmid:14566051
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Fremeaux-Bacchi V,
    2. Dragon-Durey MA,
    3. Blouin J,
    4. Vigneau C,
    5. Kuypers D,
    6. Boudailliez B,
    7. Loirat C,
    8. Rondeau E,
    9. Fridman WH
    : Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 41: e84, 2004pmid:15173250
    OpenUrlFREE Full Text
    1. Kavanagh D,
    2. Kemp EJ,
    3. Mayland E,
    4. Winney RJ,
    5. Duffield JS,
    6. Warwick G,
    7. Richards A,
    8. Ward R,
    9. Goodship JA,
    10. Goodship TH
    : Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16: 2150–2155, 2005pmid:15917334
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Goicoechea de Jorge E,
    2. Harris CL,
    3. Esparza-Gordillo J,
    4. Carreras L,
    5. Arranz EA,
    6. Garrido CA,
    7. López-Trascasa M,
    8. Sánchez-Corral P,
    9. Morgan BP,
    10. Rodríguez de Córdoba S
    : Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104: 240–245, 2007pmid:17182750
    OpenUrlAbstract/FREE Full Text
    1. Frémeaux-Bacchi V,
    2. Miller EC,
    3. Liszewski MK,
    4. Strain L,
    5. Blouin J,
    6. Brown AL,
    7. Moghal N,
    8. Kaplan BS,
    9. Weiss RA,
    10. Lhotta K,
    11. Kapur G,
    12. Mattoo T,
    13. Nivet H,
    14. Wong W,
    15. Gie S,
    16. Hurault de Ligny B,
    17. Fischbach M,
    18. Gupta R,
    19. Hauhart R,
    20. Meunier V,
    21. Loirat C,
    22. Dragon-Durey MA,
    23. Fridman WH,
    24. Janssen BJ,
    25. Goodship TH,
    26. Atkinson JP
    : Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948–4952, 2008pmid:18796626
    OpenUrlAbstract/FREE Full Text
    1. Dragon-Durey MA,
    2. Loirat C,
    3. Cloarec S,
    4. Macher MA,
    5. Blouin J,
    6. Nivet H,
    7. Weiss L,
    8. Fridman WH,
    9. Frémeaux-Bacchi V
    : Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16: 555–563, 2005pmid:15590760
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Delvaeye M,
    2. Noris M,
    3. De Vriese A,
    4. Esmon CT,
    5. Esmon NL,
    6. Ferrell G,
    7. Del-Favero J,
    8. Plaisance S,
    9. Claes B,
    10. Lambrechts D,
    11. Zoja C,
    12. Remuzzi G,
    13. Conway EM
    : Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361: 345–357, 2009pmid:19625716
    OpenUrlCrossRefPubMed
  10. ↵
    1. de Córdoba SR,
    2. de Jorge EG
    : Translational mini-review series on complement factor H: Genetics and disease associations of human complement factor H. Clin Exp Immunol 151: 1–13, 2008pmid:18081690
    OpenUrlCrossRefPubMed
  11. ↵
    1. Legendre CM,
    2. Licht C,
    3. Muus P,
    4. Greenbaum LA,
    5. Babu S,
    6. Bedrosian C,
    7. Bingham C,
    8. Cohen DJ,
    9. Delmas Y,
    10. Douglas K,
    11. Eitner F,
    12. Feldkamp T,
    13. Fouque D,
    14. Furman RR,
    15. Gaber O,
    16. Herthelius M,
    17. Hourmant M,
    18. Karpman D,
    19. Lebranchu Y,
    20. Mariat C,
    21. Menne J,
    22. Moulin B,
    23. Nürnberger J,
    24. Ogawa M,
    25. Remuzzi G,
    26. Richard T,
    27. Sberro-Soussan R,
    28. Severino B,
    29. Sheerin NS,
    30. Trivelli A,
    31. Zimmerhackl LB,
    32. Goodship T,
    33. Loirat C
    : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169–2181, 2013pmid:23738544
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lemaire M,
    2. Frémeaux-Bacchi V,
    3. Schaefer F,
    4. Choi M,
    5. Tang WH,
    6. Le Quintrec M,
    7. Fakhouri F,
    8. Taque S,
    9. Nobili F,
    10. Martinez F,
    11. Ji W,
    12. Overton JD,
    13. Mane SM,
    14. Nürnberg G,
    15. Altmüller J,
    16. Thiele H,
    17. Morin D,
    18. Deschenes G,
    19. Baudouin V,
    20. Llanas B,
    21. Collard L,
    22. Majid MA,
    23. Simkova E,
    24. Nürnberg P,
    25. Rioux-Leclerc N,
    26. Moeckel GW,
    27. Gubler MC,
    28. Hwa J,
    29. Loirat C,
    30. Lifton RP
    : Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45: 531–536, 2013pmid:23542698
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ozaltin F,
    2. Li B,
    3. Rauhauser A,
    4. An SW,
    5. Soylemezoglu O,
    6. Gonul II,
    7. Taskiran EZ,
    8. Ibsirlioglu T,
    9. Korkmaz E,
    10. Bilginer Y,
    11. Duzova A,
    12. Ozen S,
    13. Topaloglu R,
    14. Besbas N,
    15. Ashraf S,
    16. Du Y,
    17. Liang C,
    18. Chen P,
    19. Lu D,
    20. Vadnagara K,
    21. Arbuckle S,
    22. Lewis D,
    23. Wakeland B,
    24. Quigg RJ,
    25. Ransom RF,
    26. Wakeland EK,
    27. Topham MK,
    28. Bazan NG,
    29. Mohan C,
    30. Hildebrandt F,
    31. Bakkaloglu A,
    32. Huang CL,
    33. Attanasio M
    : DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 24: 377–384, 2013pmid:23274426
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Nozal P,
    2. Garrido S,
    3. Alba-Domínguez M,
    4. Espinosa L,
    5. Peña A,
    6. Córdoba SR,
    7. Sánchez-Corral P,
    8. López-Trascasa M
    : An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator. Mol Immunol 58: 194–200, 2014pmid:24378252
    OpenUrlCrossRefPubMed
  15. ↵
    1. González-Rubio C,
    2. Ferreira-Cerdán A,
    3. Ponce IM,
    4. Arpa J,
    5. Fontán G,
    6. López-Trascasa M
    : Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. Arch Neurol 58: 1923–1928, 2001pmid:11709004
    OpenUrlCrossRefPubMed
  16. ↵
    1. Abarrategui-Garrido C,
    2. Martínez-Barricarte R,
    3. López-Trascasa M,
    4. de Córdoba SR,
    5. Sánchez-Corral P
    : Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114: 4261–4271, 2009pmid:19745068
    OpenUrlAbstract/FREE Full Text
    1. López-Trascasa M,
    2. Marín MA,
    3. Fontán G
    : C3 nephritic factor determination. A comparison between two methods. J Immunol Methods 98: 77–82, 1987pmid:3559214
    OpenUrlCrossRefPubMed
  17. ↵
    1. Sánchez-Corral P,
    2. González-Rubio C,
    3. Rodríguez de Córdoba S,
    4. López-Trascasa M
    : Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 41: 81–84, 2004pmid:15140578
    OpenUrlCrossRefPubMed
  18. ↵
    1. Martínez-Barricarte R,
    2. Heurich M,
    3. Valdes-Cañedo F,
    4. Vazquez-Martul E,
    5. Torreira E,
    6. Montes T,
    7. Tortajada A,
    8. Pinto S,
    9. Lopez-Trascasa M,
    10. Morgan BP,
    11. Llorca O,
    12. Harris CL,
    13. Rodríguez de Córdoba S
    : Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120: 3702–3712, 2010pmid:20852386
    OpenUrlCrossRefPubMed
  19. ↵
    1. Tortajada A,
    2. Yébenes H,
    3. Abarrategui-Garrido C,
    4. Anter J,
    5. García-Fernández JM,
    6. Martínez-Barricarte R,
    7. Alba-Domínguez M,
    8. Malik TH,
    9. Bedoya R,
    10. Cabrera Pérez R,
    11. López Trascasa M,
    12. Pickering MC,
    13. Harris CL,
    14. Sánchez-Corral P,
    15. Llorca O,
    16. Rodríguez de Córdoba S
    : C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123: 2434–2446, 2013pmid:23728178
    OpenUrlCrossRefPubMed
  20. ↵
    1. Kumar P,
    2. Henikoff S,
    3. Ng PC
    : Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073–1081, 2009pmid:19561590
    OpenUrlCrossRefPubMed
  21. ↵
    1. Adzhubei IA,
    2. Schmidt S,
    3. Peshkin L,
    4. Ramensky VE,
    5. Gerasimova A,
    6. Bork P,
    7. Kondrashov AS,
    8. Sunyaev SR
    : A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249, 2010pmid:20354512
    OpenUrlCrossRefPubMed
  22. ↵
    1. Schwarz JM,
    2. Rödelsperger C,
    3. Schuelke M,
    4. Seelow D
    : MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 7: 575–576, 2010pmid:20676075
    OpenUrlCrossRefPubMed
  23. ↵
    1. Tavtigian SV,
    2. Deffenbaugh AM,
    3. Yin L,
    4. Judkins T,
    5. Scholl T,
    6. Samollow PB,
    7. de Silva D,
    8. Zharkikh A,
    9. Thomas A
    : Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43: 295–305, 2006pmid:16014699
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Roumenina LT,
    2. Frimat M,
    3. Miller EC,
    4. Provot F,
    5. Dragon-Durey MA,
    6. Bordereau P,
    7. Bigot S,
    8. Hue C,
    9. Satchell SC,
    10. Mathieson PW,
    11. Mousson C,
    12. Noel C,
    13. Sautes-Fridman C,
    14. Halbwachs-Mecarelli L,
    15. Atkinson JP,
    16. Lionet A,
    17. Fremeaux-Bacchi V
    : A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119: 4182–4191, 2012pmid:22246034
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Noris M,
    2. Caprioli J,
    3. Bresin E,
    4. Mossali C,
    5. Pianetti G,
    6. Gamba S,
    7. Daina E,
    8. Fenili C,
    9. Castelletti F,
    10. Sorosina A,
    11. Piras R,
    12. Donadelli R,
    13. Maranta R,
    14. van der Meer I,
    15. Conway EM,
    16. Zipfel PF,
    17. Goodship TH,
    18. Remuzzi G
    : Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844–1859, 2010pmid:20595690
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 9 (9)
Clinical Journal of the American Society of Nephrology
Vol. 9, Issue 9
September 05, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Complement Mutations in Diacylglycerol Kinase-ε–Associated Atypical Hemolytic Uremic Syndrome
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Complement Mutations in Diacylglycerol Kinase-ε–Associated Atypical Hemolytic Uremic Syndrome
Daniel Sánchez Chinchilla, Sheila Pinto, Bernd Hoppe, Marta Adragna, Laura Lopez, Maria Luisa Justa Roldan, Antonia Peña, Margarita Lopez Trascasa, Pilar Sánchez-Corral, Santiago Rodríguez de Córdoba
CJASN Sep 2014, 9 (9) 1611-1619; DOI: 10.2215/CJN.01640214

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Complement Mutations in Diacylglycerol Kinase-ε–Associated Atypical Hemolytic Uremic Syndrome
Daniel Sánchez Chinchilla, Sheila Pinto, Bernd Hoppe, Marta Adragna, Laura Lopez, Maria Luisa Justa Roldan, Antonia Peña, Margarita Lopez Trascasa, Pilar Sánchez-Corral, Santiago Rodríguez de Córdoba
CJASN Sep 2014, 9 (9) 1611-1619; DOI: 10.2215/CJN.01640214
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States
  • Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide
  • Zolpidem Versus Trazodone Initiation and the Risk of Fall-Related Fractures among Individuals Receiving Maintenance Hemodialysis
Show more Original Articles

Genetics

  • Preimplantation Genetic Testing for Monogenic Kidney Disease
  • Pilot Study of Return of Genetic Results to Patients in Adult Nephrology
  • Reverse Phenotyping after Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome
Show more Genetics

Cited By...

  • Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy
  • Thrombotic Microangiopathy and the Kidney
  • The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase {varepsilon}
  • Atypical hemolytic uremic syndrome
  • Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases
  • Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome
  • Loss of DGK{varepsilon} induces endothelial cell activation and death independently of complement activation
  • New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3
  • Factors Influencing Treatment of Atypical Hemolytic Uremic Syndrome
  • Google Scholar

Similar Articles

Related Articles

  • Factors Influencing Treatment of Atypical Hemolytic Uremic Syndrome
  • PubMed
  • Google Scholar

Keywords

  • Complement
  • genetic renal disease
  • hemolytic uremic syndrome

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire